195 related articles for article (PubMed ID: 12542524)
41. Long-term follow-up of skin cancer in the PUVA-48 cooperative study.
Forman AB; Roenigk HH; Caro WA; Magid ML
Arch Dermatol; 1989 Apr; 125(4):515-9. PubMed ID: 2649011
[TBL] [Abstract][Full Text] [Related]
42. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.
Borghi A; Corazza M; Mantovani L; Bertoldi AM; Giari S; Virgili A
Int J Dermatol; 2012 Dec; 51(12):1512-6. PubMed ID: 23171021
[TBL] [Abstract][Full Text] [Related]
43. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM; Mohammad NA; Nanu NM; Tey KE; Chew SF
Int J Dermatol; 2014 Jun; 53(6):676-84. PubMed ID: 23967807
[TBL] [Abstract][Full Text] [Related]
44. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
[TBL] [Abstract][Full Text] [Related]
45. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
Naldi L; Griffiths CE
Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088
[TBL] [Abstract][Full Text] [Related]
46. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
Ahlehoff O; Skov L; Gislason G; Lindhardsen J; Kristensen SL; Iversen L; Lasthein S; Gniadecki R; Dam TN; Torp-Pedersen C; Hansen PR
J Intern Med; 2013 Feb; 273(2):197-204. PubMed ID: 22963528
[TBL] [Abstract][Full Text] [Related]
48. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
[TBL] [Abstract][Full Text] [Related]
49. CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy.
Yıldırım FE; Karaduman A; Pinar A; Aksoy Y
Int J Dermatol; 2011 Aug; 50(8):948-55. PubMed ID: 21781066
[TBL] [Abstract][Full Text] [Related]
50. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
[TBL] [Abstract][Full Text] [Related]
51. Risk of skin tumors in psoralen- and ultraviolet A-treated patients.
Henseler T; Christophers E
Natl Cancer Inst Monogr; 1984 Dec; 66():217-9. PubMed ID: 6531033
[TBL] [Abstract][Full Text] [Related]
52. PUVA treatment and skin cancer: A follow-up study.
Lassus A; Reunala T; Idänpää-Heikkilä J; Juvakoski T; Salo O
Acta Derm Venereol; 1981; 61(2):141-5. PubMed ID: 6165190
[TBL] [Abstract][Full Text] [Related]
53. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
Long A; Rahmaoui A; Rothman KJ; Guinan E; Eisner M; Bradley MS; Iribarren C; Chen H; Carrigan G; Rosén K; Szefler SJ
J Allergy Clin Immunol; 2014 Sep; 134(3):560-567.e4. PubMed ID: 24679845
[TBL] [Abstract][Full Text] [Related]
54. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.
Hearn RM; Kerr AC; Rahim KF; Ferguson J; Dawe RS
Br J Dermatol; 2008 Sep; 159(4):931-5. PubMed ID: 18834483
[TBL] [Abstract][Full Text] [Related]
55. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
Nijsten T; Margolis DJ; Feldman SR; Rolstad T; Stern RS
J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):434-44. PubMed ID: 15761421
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous carcinoma and 8-methoxypsoralen and ultraviolet A (PUVA) lentigines in Japanese patients with psoriasis treated with topical PUVA: a follow-up study of 214 patients.
Takashima A; Matsunami E; Yamamoto K; Kitajima S; Mizuno N
Photodermatol Photoimmunol Photomed; 1990 Oct; 7(5):218-21. PubMed ID: 2091746
[TBL] [Abstract][Full Text] [Related]
57. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
[TBL] [Abstract][Full Text] [Related]
58. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
59. The risk of malignancy associated with psoriasis.
Margolis D; Bilker W; Hennessy S; Vittorio C; Santanna J; Strom BL
Arch Dermatol; 2001 Jun; 137(6):778-83. PubMed ID: 11405770
[TBL] [Abstract][Full Text] [Related]
60. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study.
Nijsten TE; Stern RS
J Am Acad Dermatol; 2003 Oct; 49(4):644-50. PubMed ID: 14512910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
